| 000 | 01318 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250513202000.0 | ||
| 264 | 0 | _c20000303 | |
| 008 | 200003s 0 0 eng d | ||
| 022 | _a0002-8703 | ||
| 024 | 7 |
_a10.1067/mhj.2000.103742 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTcheng, J E | |
| 245 | 0 | 0 |
_aClinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. _h[electronic resource] |
| 260 |
_bAmerican heart journal _cFeb 2000 |
||
| 300 |
_aS38-45 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aEptifibatide |
| 650 | 0 | 4 |
_aHemorrhage _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMyocardial Ischemia _xblood |
| 650 | 0 | 4 |
_aPeptides _xadverse effects |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aPlatelet Glycoprotein GPIIb-IIIa Complex _xantagonists & inhibitors |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aThrombocytopenia _xchemically induced |
| 650 | 0 | 4 | _aTirofiban |
| 650 | 0 | 4 |
_aTyrosine _xadverse effects |
| 773 | 0 |
_tAmerican heart journal _gvol. 139 _gno. 2 Pt 2 _gp. S38-45 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1067/mhj.2000.103742 _zAvailable from publisher's website |
| 999 |
_c10605352 _d10605352 |
||